Comparison of Chemotherapy Combined With Chidamide Versus Chemotherapy in the Frontline Treatment for Peripheral T-Cell Lymphoma

BACKGROUND: Peripheral T-cell lymphoma (PTCL) is featured with a poor survival outcome. China has approved chidamide, an oral novel histone deacetylase inhibitor, for patients diagnosed with relapsed or refractory PTCL. OBJECTIVE: We compared the benefit of traditional chemotherapy alone and a combi...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jinni, Su, Ning, Fang, Yu, Ma, Shuyun, Zhang, Yuchen, Cai, Jun, Zou, Qihua, Tian, Xiaopeng, Xia, Yi, Liu, Panpan, Li, Zhiming, Huang, He, Huang, Huiqiang, Cai, Qingqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8847145/
https://www.ncbi.nlm.nih.gov/pubmed/35185926
http://dx.doi.org/10.3389/fimmu.2022.835103

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8847145/
https://www.ncbi.nlm.nih.gov/pubmed/35185926
http://dx.doi.org/10.3389/fimmu.2022.835103

Ejemplares similares